Kelsey S. Lau-Min, MD, MSCE is a Senior Research Fellow in the Division of Hematology and Oncology at the Univ... Read Bio
This project is funded under the Robert Wood Johnson Foundation’s research program, “Health Data for Action (HD4A),” which makes valuable data from unique data owners available to researchers to answer important research questions. The goal of the study is to inform value-based drug pricing policies and provide insights into how to balance the prioritization of high-value targeted cancer drugs with the financial burden of these therapies on patients. Using HCCI data and the ASCO value framework, the researchers would (1) compare the uptake of high-, medium-, and low-value targeted cancer drugs over time; and (2) determine the impact of targeted cancer drug value on patient out-of-pocket spending. Deliverables will include a project work plan and final narrative. The researchers will also produce paper(s) suitable for publication and present findings at national research meetings and to other stakeholder audiences as appropriate, including policymakers at the federal, state, and local levels and other key stakeholders, as part of the deliverables for this grant.
Grantee Organization: University of Pennsylvania
Grantee period: 12/1/2021– 5/31/2023